Suggested remit - To appraise the clinical and cost effectiveness of solriamfetol within its marketing authorisation for treating excessive sleepiness caused by narcolepsy or obstructive sleep apnoea
Status In progress
Process STA 2018
ID number 1499

Provisional Schedule

Expected publication 27 January 2021

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
10 December 2019 In progress, Referred April 2019
18 October 2019 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of solriamfetol for treating excessive waketime sleepiness caused by obstructive sleep apnoea. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early March 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
14 January 2019 (14:00) Scoping workshop (Manchester)
16 November 2018 - 14 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance